MedDataX Logo

Evaluation of Galectin-3 Levels in GCF And Saliva of Patients With Different Periodontal Diseases

NCT ID: NCT05281796

Last Updated: 2023-11-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

66 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-22

Study Completion Date

2023-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the levels of galectin-3 in the GCF and saliva in patient with gingivitis and patient with stage III periodontitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to assess the levels of galectin-3 in the GCF and saliva in patient with gingivitis and patient with stage III periodontitis.

This study will be conducted in the Oral Medicine and Periodontology department, Faculty of Dentistry- Cairo University, Egypt.

Patients will be selected from the outpatient clinic of the department of Oral Medicine and Periodontology, Faculty of Dentistry-Cairo University.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontal Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

healthy patient

Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained

GCF obtaining

Intervention Type DIAGNOSTIC_TEST

GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

saliva obtaining

Intervention Type DIAGNOSTIC_TEST

Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

gingivitis patient

Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained

GCF obtaining

Intervention Type DIAGNOSTIC_TEST

GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

saliva obtaining

Intervention Type DIAGNOSTIC_TEST

Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

patients with Stage III periodontitis

Full-mouth clinical periodontal measurements recorded, saliva and GCF obtained

GCF obtaining

Intervention Type DIAGNOSTIC_TEST

GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

saliva obtaining

Intervention Type DIAGNOSTIC_TEST

Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GCF obtaining

GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

Intervention Type DIAGNOSTIC_TEST

saliva obtaining

Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. For healthy group: individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study.
2. For the gingivitis group: individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss.
3. For the periodontitis group that has not received periodontal treatment in the last 6 months
4. For the periodontitis group: individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss.
5. Presence of a minimum of 15 natural teeth.

Exclusion Criteria

1. Individuals with any known systemic disease.
2. Pregnant and lactating women.
3. Individuals that received periodontal treatment within the last 6 months.
4. Individuals with a history of systemic antibiotics and anti-inflammatory drugs within the last 3 months.
5. Former or current smokers.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed saad arafa ali

Principal Investigator mohamed saad

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohamed Sa Ali, master's

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cairo university Faculty of dentistry

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1512022

Identifier Type: -

Identifier Source: org_study_id